Sotyktu floundering

Quote




Not true. I’m a consultant with BMS, Commercial US Dermatogy will remain untouched and will continue to increase access. ELT is looking for Derm to continue to grow through 2025 and with PsA.
 



anonymous said:
Not true. I’m a consultant with BMS, Commercial US Dermatogy will remain untouched and will continue to increase access. ELT is looking for Derm to continue to grow through 2025 and with PsA.
Click to expand...
I agree. Derm is safe. They need the sales force for the launch. Now that the Orencia sales team is back they will show Dermatology how to really sell a product. I can guarantee the Rheum reps will out perform the Derm reps with this PSA launch.
 



anonymous said:
I agree. Derm is safe. They need the sales force for the launch. Now that the Orencia sales team is back they will show Dermatology how to really sell a product. I can guarantee the Rheum reps will out perform the Derm reps with this PSA launch.
Click to expand...
WHY ON GOD'S GOOD GREEN EARTH WOULD A RHEUMATOLOGIST PRESCRIBE SOTYKTU FOR PSA WHEN THEY HAVE 47 BETTER OPTIONS FOR PSA?
 









Apremilast gets 87% of its volume from dermatology, 7% from rheumatology and 6% from other.

Rheums have dozens of better options, even orals ones, that both apremilast and deucra.

Still, almost anyone will be better than our derm sales force. Clown show.
 



anonymous said:
Apremilast gets 87% of its volume from dermatology, 7% from rheumatology and 6% from other.

Rheums have dozens of better options, even orals ones, that both apremilast and deucra.

Still, almost anyone will be better than our derm sales force. Clown show.
Click to expand...
Actually, you have it all wrong. The sales force will prove to be the only reason we succeed as it is surely not going to be consistency in hiring strong leadership, competent ELT, accurate forecasting, understanding access or formularies (insurance, hospital, or office) or Rx pull-through.
 



Top Bottom
Back
Quote